Hogan Lovells

Jason F. Conaty

Counsel
Washington, D.C.

Phone
+1 202 637 3237

Fax
+1 202 637 5910

Email
jason.conaty@hoganlovells.com

Biography

With over seven years of immersive lawyering in the FDA regulatory arena, Jason Conaty works with pharma and biotech companies to solve the myriad of problems they face in the often decades-long struggle to bring innovative new medicines from the laboratory bench, into the clinic, and on into the marketplace. Jason helps these companies navigate the thicket of laws and regulations that lie between the discovery of an important new drug, and the patient who needs it.

Before heading to law school, Jason was a bench scientist, working and publishing in the field of nucleic acid chemistry and rational drug design. He completed his Ph.D. in Australia before settling in the United States to take a position at Massachusetts General Hospital, where he was a Fellow of the Leukemia and Lymphoma Society, and a Fellow in Genetics at Harvard Medical School.

As a scientist and a lawyer, Jason has advised and advocated on countless scientific and regulatory matters in the life sciences and biotechnology space. Concentrating on the development, approval, and marketing of complex therapeutic products, Jason has deep experience on lifecycle management issues relating to drugs, biologics, and drug-device combination products.

Practices

Pharmaceuticals and Biotechnology Regulatory

Industries

Life Sciences and Health Care

Areas of focus

Pharmaceuticals and Biotechnology

Cell, Tissue, and Gene Therapies

Combination Products

While at law school, Jason clerked for the United States Senate Judiciary Committee, in the office of Senator Edward M. Kennedy. He remains committed to prisoner rights and fair sentencing issues through his pro bono practice.

Representative experience

Advocated before FDA's Exclusivity Board regarding the application of marketing exclusivity to a newly approved product.

Solved a scientific impasse with FDA using the agency's Formal Dispute Resolution process, leading to the approval of a small company's drug product.

Advises a major pharma company on the implications of the BPCIA to its product pipeline.

Latest thinking and events

- News
  - Federal court limits FDA discretion in “drug” vs. “device” classification
- News
  - Biden signs bill limiting new drug exclusivity awards to innovations in active moiety
- Hogan Lovells Publications
  - Life sciences and health care horizons 2021
- News
  - New Orange & Purple Book laws increase transparency of patent information for drugs, biologics
- Press Releases
  - Hogan Lovells welcomes the New Year and 25 new partner and 60 new counsel promotions
- News
  - Labeling carve-out does not shield generic drug makers from induced infringement claims, CAFC rules

Education and admissions

Education

J.D., Georgetown University Law Center, cum laude, 2007

Ph.D. Biochemistry, University of New South Wales, Australia, 2000

B.S., University of Technology, Sydney, first class honors, 1995

Bar admissions and qualifications

District of Columbia

New York